lansoprazole has been researched along with Local Neoplasm Recurrence in 4 studies
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this phase 3, randomized (1:1), double-blind, double-dummy, parallel-group, non-inferiority study (April 5, 2017, to July 19, 2019), patients with ≥ 1 endoscopically confirmed duodenal ulcer, at 52 hospitals (China, South Korea, and Taiwan), received vonoprazan 20 mg once daily (QD) or lansoprazole 30 mg QD for 6 weeks maximum." | 9.51 | Vonoprazan non-inferior to lansoprazole in treating duodenal ulcer and eradicating Helicobacter pylori in Asian patients. ( Chiu, CT; Chong, CF; Chung, WC; Gu, L; Hou, X; Kudou, K; Meng, F; Sha, W; Wang, J; Zhang, S, 2022) |
| "In this phase 3, randomized (1:1), double-blind, double-dummy, parallel-group, non-inferiority study (April 5, 2017, to July 19, 2019), patients with ≥ 1 endoscopically confirmed duodenal ulcer, at 52 hospitals (China, South Korea, and Taiwan), received vonoprazan 20 mg once daily (QD) or lansoprazole 30 mg QD for 6 weeks maximum." | 5.51 | Vonoprazan non-inferior to lansoprazole in treating duodenal ulcer and eradicating Helicobacter pylori in Asian patients. ( Chiu, CT; Chong, CF; Chung, WC; Gu, L; Hou, X; Kudou, K; Meng, F; Sha, W; Wang, J; Zhang, S, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hou, X | 1 |
| Meng, F | 1 |
| Wang, J | 1 |
| Sha, W | 1 |
| Chiu, CT | 1 |
| Chung, WC | 1 |
| Gu, L | 1 |
| Kudou, K | 1 |
| Chong, CF | 1 |
| Zhang, S | 1 |
| Tuyaerts, S | 1 |
| Van Nuffel, AMT | 1 |
| Naert, E | 1 |
| Van Dam, PA | 1 |
| Vuylsteke, P | 1 |
| De Caluwé, A | 1 |
| Aspeslagh, S | 1 |
| Dirix, P | 1 |
| Lippens, L | 1 |
| De Jaeghere, E | 1 |
| Amant, F | 1 |
| Vandecasteele, K | 1 |
| Denys, H | 1 |
| Fukase, K | 1 |
| Kato, M | 1 |
| Kikuchi, S | 1 |
| Inoue, K | 1 |
| Uemura, N | 1 |
| Okamoto, S | 1 |
| Terao, S | 1 |
| Amagai, K | 1 |
| Hayashi, S | 1 |
| Asaka, M | 1 |
| Hamaguchi, K | 1 |
| Ogawa, K | 1 |
| Katsube, T | 1 |
| Konno, S | 1 |
| Aiba, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Investigation of Pembrolizumab (Keytruda) in Combination With Radiation and an Immune Modulatory Cocktail in Patients With Cervical and Uterine Cancer (PRIMMO Trial)[NCT03192059] | Phase 2 | 43 participants (Actual) | Interventional | 2017-07-01 | Completed | ||
| Prediction for the Development of Metachronous Gastric Cancer After Endoscopic Submucosal Dissection by Serum Pepsinogen[NCT02682446] | 800 participants (Actual) | Observational | 2007-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for lansoprazole and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Vonoprazan non-inferior to lansoprazole in treating duodenal ulcer and eradicating Helicobacter pylori in Asian patients.
Topics: Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Duod | 2022 |
PRIMMO study protocol: a phase II study combining PD-1 blockade, radiation and immunomodulation to tackle cervical and uterine cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Aspirin; Chemoradiotherapy; Curcumin; Cycl | 2019 |
Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Infective Agents; Clarithromycin; Endoscopy, Gas | 2008 |
1 other study available for lansoprazole and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Does eradication of Helicobacter pylori reduce the risk of carcinogenesis in the residual stomach after gastrectomy for early gastric cancer? Comparison of mucosal lesions in the residual stomach before and after Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenocarcinoma; Aged; Amoxicillin; Anti-Bacterial Agents; A | 2004 |